← Back to All US Stocks

LakeShore Biopharma Co., Ltd. (LSBWF) Fundamental Analysis & AI Grade 2026

LSBWF OTC Pharmaceutical Preparations E9 CIK: 0001946399
Recently Updated • Analysis: Jul 13, 2026 • SEC Data: 2026-07-13

LakeShore Biopharma Co., Ltd. (LSBWF) Financial Metrics & Key Ratios

Revenue
N/A
Net Income
N/A
EPS (Diluted)
$0.00
Free Cash Flow
N/A
Total Assets
N/A
Cash Position
N/A

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

LSBWF Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA N/A
FCF Margin N/A

LSBWF vs Healthcare Sector: How LakeShore Biopharma Co., Ltd. Compares

How LakeShore Biopharma Co., Ltd. compares to Healthcare sector averages

Net Margin
LSBWF 0.0%
vs
Sector Avg 12.0%
LSBWF Sector
ROE
LSBWF 0.0%
vs
Sector Avg 15.0%
LSBWF Sector
Current Ratio
LSBWF 0.0x
vs
Sector Avg 2.0x
LSBWF Sector
Debt/Equity
LSBWF 0.0x
vs
Sector Avg 0.6x
LSBWF Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is LakeShore Biopharma Co., Ltd. Stock Overvalued? LSBWF Valuation Analysis 2026

Based on fundamental analysis, LakeShore Biopharma Co., Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
N/A
Sector avg: 15%
Net Profit Margin
N/A
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

LakeShore Biopharma Co., Ltd. Balance Sheet: LSBWF Debt, Cash & Liquidity

Current Ratio
N/A
Quick Ratio
N/A
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A

LSBWF Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

LSBWF SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for LakeShore Biopharma Co., Ltd. (CIK: 0001946399)

📋 Recent SEC Filings

Date Form Document Action
Feb 15, 2024 SC 13G tm246234d1_sc13g.htm View →
Feb 14, 2024 SC 13D ea193507-13dwong_ysbio.htm View →

Frequently Asked Questions about LSBWF

What is the AI rating for LSBWF?

LakeShore Biopharma Co., Ltd. (LSBWF) has an AI grade of N/A with 0% confidence, based on fundamental analysis of SEC EDGAR filings.

What are LSBWF's key strengths?

Claude: Analysis in progress.

What are the risks of investing in LSBWF?

Claude: Analysis in progress.

What is LSBWF's revenue and growth?

LakeShore Biopharma Co., Ltd. reported revenue of N/A.

Does LSBWF pay dividends?

LakeShore Biopharma Co., Ltd. does not currently pay dividends.

Where can I find LSBWF SEC filings?

Official SEC filings for LakeShore Biopharma Co., Ltd. (CIK: 0001946399) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is LSBWF's EPS?

LakeShore Biopharma Co., Ltd. has a diluted EPS of $0.00.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.

What is LSBWF's fundamental grade?

Based on our AI fundamental analysis in July 2026, LakeShore Biopharma Co., Ltd. has a N/A grade with 0% confidence. Review the strengths and risks sections above for full context. This is not investment advice.

Is LSBWF stock overvalued or undervalued?

Valuation metrics for LSBWF: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

What is LSBWF's AI grade for 2026?

Our dual AI analysis gives LakeShore Biopharma Co., Ltd. a combined N/A grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is LSBWF's free cash flow?

LakeShore Biopharma Co., Ltd.'s operating cash flow is N/A, with capital expenditures of N/A.

How does LSBWF compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).

Top Rated Stocks
AAPL 92% MSFT 92% FAST 92% ANET 88% RDDT 88% KNSL 88% MGRE 88% FIZZ 88% CRDO 87% AVGO 87%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Jul 13, 2026 | Data as of: 2026-07-13 | Powered by Claude AI